Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

MDxHealth SA

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

APPOINTMENT OF EXECUTIVE CHAIRMAN, PROPOSED CHANGE OF NAME AND STRATEGY UPDATE COMPANY TO PURSUE REVISED STRATEGY AND NAME CHANGE TO CELLBXHEALTH PLC DR. JAN GROEN, THE CURRENT NON-EXECUTIVE CHAIRMAN AND RECOGNISED ONCOLOGY DIAGNOSTIC INDUSTRY VETERAN, TO LEAD COMPANY AS EXECUTIVE CHAIRMAN REVISED STRATEGY TO SHARPEN FOCUS ON THE PROVISION OF INDUSTRY-LEADING CTC INTELLIGENCE AND ACCELERATE COMPANY'S COMMERCIAL TRACTION, WHILST DELIVERING FURTHER COST CONTROL CASH RUNWAY REMAINS THROUGH TO Q1 2026; EXPECTED NEED TO RAISE FUNDS IN COMING MONTHS GUILDFORD, SURREY / ACCESS NEWSWIRE / OCTOBER 8, 2025 / ANGLE PLC (AIM:AGL)(OTCQX:ANPCY), A GLOBAL PRECISION CTC INTELLIGENCE COMPANY SPECIALISING IN INNOVATIVE CIRCULATING TUMOUR CELL (CTC) SOLUTIONS FOR USE IN RESEARCH, DRUG DEVELOPMENT AND CLINICAL ONCOLOGY, ANNOUNCES THAT ITS CHAIRMAN, DR JAN GROEN, HAS MOVED INTO AN EXECUTIVE ROLE. JAN WILL LEAD THE COMPANY AS IT PURSUES A REVISED STRATEGY, FOCUSED ON TIGHT COST CONTROL, ACCELERATED COMMERCIAL PROGRESS AND A CLEAR PLAN TOWARDS BECOMING A SUSTAINABLE BUSINESS.

ANGLE PLC ANNOUNCES STRATEGY UPDATE

M DXH EALTH REPORTS PRELIMINARY SECOND QUARTER 202 5 RESULTS , REACHES POSITIVE ADJUSTED EBITDA , AND A NNOUNCES ACQUISITION OF EXO SOME D IAGNOSTICS B USINESS FROM BIO - TECHNE

MDXHEALTH REPORTS PRELIMINARY SECOND QUARTER 2025 RESULTS, REACHES POSITIVE ADJUSTED EBITDA, AND ANNOUNCES ACQUISITION OF EXOSOME DIAGNOSTICS BUSINESS FROM BIO-TECHNE

IRVINE, CA, AND HERSTAL, BELGIUM  JULY 3, 2025 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (THE "COMPANY" OR "MDXHEALTH"), A LEADING PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF MICHAEL HOLDER TO ITS BOARD OF DIRECTORS AS THE CHAIR OF THE AUDIT COMMITTEE. MR. HOLDER WILL TAKE THE SEAT OF REGINE SLAGMULDER, WHOSE TERM COMPLETED IN MAY.

MDXHEALTH APPOINTS MICHAEL HOLDER TO BOARD OF DIRECTORS AND ANNOUNCES MANAGEMENT CHANGE

YEAR-OVER-YEAR Q1 REVENUES INCREASE BY 22% TO $24.3 MILLION 71% YEAR-OVER-YEAR IMPROVEMENT IN ADJUSTED EBITDA IN FIRST QUARTER CONFERENCE CALL WITH Q&A TODAY AT 4:30 PM ET / 22:30 CET

MDXHEALTH REPORTS Q1-2025 RESULTS

FOURTH QUARTER REVENUE GROWTH OF 28% TO $24.7 MILLION 2024 REVENUE GROWTH OF 28% TO $90.0 MILLION 68% IMPROVEMENT IN ADJUSTED EBITDA IN FOURTH QUARTER CONFERENCE CALL WITH Q&A TODAY AT 4:30 PM EST / 22:30 CET

MDXHEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS

MDXHEALTH REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2024 REVENUES AND ISSUES 2025 REVENUE GUIDANCE IRVINE, CA  JANUARY 13, 2025 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (THE "COMPANY" OR "MDXHEALTH"), A LEADING PRECISION DIAGNOSTICS COMPANY, TODAY REPORTED PRELIMINARY FOURTH QUARTER AND FULL YEAR 2024 REVENUES AND ISSUED 2025 REVENUE GUIDANCE. THE COMPANY EXPECTS TO REPORT FOURTH QUARTER AND FULL YEAR 2024 REVENUES OF APPROXIMATELY $24.7 AND $90.0 MILLION, RESPECTIVELY, REPRESENTING YEAR-OVER-YEAR GROWTH OF 28% FOR BOTH PERIODS.

MDXHEALTH REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2024 REVENUES AND ISSUES 2025 REVENUE GUIDANCE

MDXHEALTH TO PARTICIPATE IN PIPER SANDLER HEALTHCARE CONFERENCE IRVINE, CA  NOVEMBER 25, 2024 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (THE "COMPANY" OR "MDXHEALTH"), A LEADING PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED THAT MICHAEL K. MCGARRITY, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN THE PIPER SANDLER 36TH ANNUAL HEALTHCARE CONFERENCE, WHICH WILL TAKE PLACE BETWEEN DEC 3-5, 2024, IN NEW YORK CITY.

MDXHEALTH TO PARTICIPATE IN PIPER SANDLER HEALTHCARE CONFERENCE

TISSUE-BASED TEST VOLUMES INCREASE BY 36%, LIQUID-BASED TEST VOLUMES BY 24% COMPANY RAISES 2024 REVENUE GUIDANCE TO $87-89 MILLION, REPRESENTING 25% GROWTH PRO-FORMA CASH OF $53.5 MILLION CONFERENCE CALL AND WEBCAST TODAY AT 4:30PM ET IRVINE, CA  NOVEMBER 6, 2024 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (THE "COMPANY" OR "MDXHEALTH"), A LEADING PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2024. MICHAEL K.

MDXHEALTH REPORTS RESULTS FOR THE THIRD QUARTER AND NINE-MONTH PERIOD ENDED SEPTEMBER 30, 2024

MDXHEALTH ANNOUNCES PRICING OF OFFERING OF ORDINARY SHARES IRVINE, CA, AND HERSTAL, BELGIUM SEPTEMBER 25, 2024 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (MDXHEALTH OR THE COMPANY), A COMMERCIAL-STAGE PRECISION DIAGNOSTICS COMPANY, TODAY ANNOUNCED THAT IT HAS PRICED A REGISTERED PUBLIC OFFERING OF 20,000,000 ORDINARY SHARES OF THE COMPANY WITHOUT NOMINAL VALUE (ORDINARY SHARES) IN A REGISTERED PUBLIC OFFERING (THE OFFERING) AT A PRICE TO THE PUBLIC OF $2.00 PER ORDINARY SHAREFOR TOTAL GROSS PROCEEDS OF $40.0 MILLIONBEFORE DEDUCTING COMMISSIONS AND ESTIMATED OFFERING EXPENSES. A STRATEGIC PARTNER IS PURCHASING 1,500,000 ORDINARY SHARES IN THIS OFFERING DIRECTLY FROM THE COMPANY RATHER THAN THROUGH THE UNDERWRITERS.

MDXHEALTH ANNOUNCES PRICING OF OFFERING OF ORDINARY SHARES

MDXHEALTH ANNOUNCES LAUNCH OF OFFERING OF ORDINARY SHARES IRVINE, CA, AND HERSTAL, BELGIUMSEPTEMBER 25, 2024 (GLOBENEWSWIRE)  MDXHEALTH SA (NASDAQ: MDXH) (MDXHEALTH OR THE COMPANY), A COMMERCIAL-STAGE PRECISION DIAGNOSTICS COMPANY, ANNOUNCED THE LAUNCH OF A PROPOSED OFFERING OF $40.0 MILLION OF ORDINARY SHARES OF THE COMPANY WITHOUT NOMINAL VALUE ("ORDINARY SHARES") IN A REGISTERED PUBLIC OFFERING (THE OFFERING). THE COMPANY ALSO EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 15% OF THE ORDINARY SHARES BEING OFFERED, EXCLUDING ANY ORDINARY SHARES PURCHASED DIRECTLY FROM THE COMPANY IN THE OFFERING PURSUANT TO ANY SEPARATE SECURITIES PURCHASE AGREEMENT.

MDxHealth SA

MDXH

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MDxHealth SA

MDXH.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MDXH